Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has today announced that its drug development holding, ReceptoPharm, has successfully completed enrollment in its phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN).
“We are pleased to have completed enrollment in our AMN trial,” commented Paul Reid, CEO of ReceptoPharm, Inc. “While many of the patients have already reached the first 3-month assessment point, completing this process now allows us to better understand the timeframe for completing the trial,” he added.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades. AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS).
“We feel that it’s important to collect as much early information as possible about the results of this trial,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corp. “For this reason, we’re expecting to conduct an interim assessment once the final patient completes 6-months of the trial. This will help us to better direct our clinical development of RPI-78M, our lead drug candidate for the treatment of neurological disorders,” he concluded.
Recently, ReceptoPharm completed successful joint venture meetings in China with Nanogene Biotechnology to develop RPI-MN for the Chinese market. RPI-MN is ReceptoPharm’s lead drug candidate being researched for the treatment of HIV/AIDS and other viral disorders. According to a recent report published by the Chinese government and the World Health Organization, over 650,000 people in China are living with HIV, although it is believed that this number is grossly underestimated.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Completed enrollment in the AMN trial should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.